
FDA Grants Priority Review to Bristol Myers Squibb’s Opdivo® Plus Chemo for Hodgkin Lymphoma
FDA Grants Priority Review to Bristol Myers Squibb’s Opdivo® (nivolumab) Plus Chemotherapy for Classical Hodgkin Lymphoma Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has…










